Results 51 to 60 of about 234,795 (273)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Comparison of treatment response between thick and thin plaque psoriasis.

, 2015
(A) Percent improvement in Psoriasis Area Severity Index (PASI) is compared between Etanercept (12 with thick plaque psoriasis and 15 with thin plaque psoriasis) and Ustekinumab 90 mg treatment (12 with thick plaque psoriasis and with 12 thin plaque ...
Mayte Suárez-Fariñas (27734), Joel Correa da Rosa (770765), Pranay Nadella (770763), Jaehwan Kim (469013), Dong Joo Kim (770764), James G. Krueger (137246), Carrie Brodmerkel (137250)   +6 more
core   +1 more source

Small plaque psoriasis re‐visited: A type of psoriasis mediated by a type‐I interferon pathway

, 2022
TNF alpha-inhibitor-induced psoriasis is mediated by the type-I interferon pathway, of which IFN alpha, LL37 and IL-36 gamma are major players. A subset of patients treated with TNF alpha inhibitors develop small plaque psoriatic lesions.
Magdalena Martinka, Jan P. Dutz, Martinka, Magdalena, Khosravi-Hafshejani, Touraj, Dutz, Jan P., Ghoreishi, Mehran, Cristian Vera Kellet, Kellet, Cristian Vera, Richard I. Crawford, Crawford, Richard, I, Mehran Ghoreishi, Touraj Khosravi‐Hafshejani   +11 more
core   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis

Pifu-xingbing zhenliaoxue zazhi
Objective To observe the clinical efficacy and safety of guselkumab injection in the treatment of moderate to severe plaque psoriasis. Methods Twenty three patients with moderate to severe plaque psoriasis were treated with subcutaneous injection of ...
Liye XIA, Linchan FAN, Weiping WANG, Zhiwei SHANG   +3 more
doaj   +1 more source

Polymorphisms in IL36G gene are associated with plaque psoriasis

BMC Medical Genetics, 2019
Background Plaque psoriasis is a non-contagious skin disease in which characteristic red and flaky lesions result from a dysregulation involving both innate and adaptive immune mechanisms.
Tanel Traks, Maris Keermann, Ele Prans, Maire Karelson, Ulvi Loite, Gea Kõks, Helgi Silm, Sulev Kõks, Külli Kingo   +8 more
doaj   +1 more source

A multicenter, controlled, randomized trial of home‐applied dual‐light photodynamic therapy in stage I to III periodontitis (LumoNorth2022 study)

Journal of Periodontology, EarlyView.
Abstract Background Periodontitis is a widespread, chronic infection‐triggered inflammatory condition in which professional supportive periodontal care (SPC) and daily oral hygiene form the backbone to reduce the disease activity. Light‐based treatments have shown promising antibacterial effects, but their potential for routine home use has not been ...
Paula Tegelberg, Meeri Ojala, Merja Ylipalosaari, Jori Lindroth, Anna Maria Heikkinen, Hanna Lähteenmäki, Saila Pakarinen, Ismo T. Räisänen, Timo Sorsa, Tommi Pätilä   +9 more
wiley   +1 more source

Diet and physical exercise in psoriasis: a randomized controlled trial

, 2014
BACKGROUND: Increased body mass index and weight gain are risk factors for psoriasis, and the prevalence of obesity in patients with psoriasis is higher than in the general population. Limited data exist regarding the role of diet in psoriasis.
Pazzaglia M, Veneziano L, NALDI, LUCIANA, Lanzoni A, Conti A, PATRIZI, ANNALISA, Pellacani G, the Psoriasis Emilia Romagna Study Group, Cazzaniga S   +8 more
core   +2 more sources

Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine

Trials, 2020
Background Plaque psoriasis is a refractory inflammatory skin disease. The common therapies used to treat plaque psoriasis in traditional Chinese medicine (TCM) and western medicine (WM) have distinct characteristics and advantages.
Xiaoying Sun, Xiaoyong Zhou, Yuegang Wei, Wenxin Yang, Ning Huang, Yangfeng Ding, Rongyi Hu, Shun Guo, Chunyan Yang, Huilan Weng, Ying Zhang, Xi Chen, Xiaojie Ding, Liu Liu, Qingfeng Yin, Ruiping Wang, Xin Li, Bin Li   +17 more
doaj   +1 more source

Analysis of Factors Influencing Clinical Types of Psoriasis Vulgaris [PDF]

, 2008
Background: Psoriasis is a chronic relapsing disorder which is influenced by various external factors. Korean psoriasis vulgaris are characterized by smaller sized plaques than those of Western population and this type of psoriasis was reported to be ...
유욱
core